Table 3.
Change of endogenous biomarkers over 12 weeks
| Coefficient | Ratio of geometric mean [95%CI] | P‐value |
|---|---|---|
| Ghrelin | ||
| (Intercept) | 4.23 [2.10–8.54] | <0.001 |
| Baseline value | 1.73 [1.61–1.86] | <0.001 |
| Treatment group (ET) | 1.09 [1.02–1.17] | 0.013 |
| Leptin | ||
| (Intercept) | 6.54 [2.59–16.55] | <0.001 |
| Baseline value | 1.78 [1.67–1.90] | <0.001 |
| Treatment group (ET) | 0.85 [0.68–1.06] | 0.15 |
| Adiponectin | ||
| (Intercept) | 6.27 [1.76–22.26] | 0.005 |
| Baseline value | 1.74 [1.58–1.92] | <0.001 |
| Treatment group (ET) | 0.89 [0.74–1.07] | 0.20 |
| TNF‐α | ||
| (Intercept) | 2.06 [1.56–2.71] | <0.001 |
| Baseline value | 1.26 [1.10–1.44] | 0.001 |
| Treatment group (ET) | 0.77 [0.57–1.04] | 0.09 |
| IL‐6 | ||
| (Intercept) | 1.13 [0.77–1.66] | 0.51 |
| Baseline value | 1.84 [1.53–2.22] | <0.001 |
| Treatment group (ET) | 0.83 [0.53–1.30] | 0.41 |
| IL‐10 | ||
| (Intercept) | 0.11 [0.01–2.04] | 0.12 |
| Baseline value | 1.41 [0.80–2.49] | 0.20 |
| Treatment group (ET) | 10.02 [0.88–114.09] | 0.06 |
| MR‐proANP | ||
| (Intercept) | 1.06 [0.35–3.16] | 0.92 |
| Baseline value | 1.94 [1.66–2.27] | <0.001 |
| Treatment group (ET) | 1.08 [0.89–1.31] | 0.44 |
| MR‐proADM | ||
| (Intercept) | 1.15 [1.05–1.25] | 0.004 |
| Baseline value | 2.14 [1.97–2.34] | <0.001 |
| Treatment group (ET) | 1.00 [0.94–1.07] | 0.99 |
| CT‐proET1 | ||
| (Intercept) | 1.24 [0.60–2.57] | 0.55 |
| Baseline value | 1.93 [1.71–2.19] | <0.001 |
| Treatment group (ET) | 1.03 [0.96–1.10] | 0.47 |
| CT‐proAVP | ||
| (Intercept) | 1.14 [0.90–1.45] | 0.26 |
| Baseline value | 1.80 [1.64–1.97] | <0.001 |
| Treatment group (ET) | 1.10 [0.91–1.33] | 0.34 |
ET, exercise training; TNF, tumour necrosis factor; UC, usual care.
Tabulated is for each measurement the ratio of geometric mean and P‐values of the group difference between the two arms [UC vs. ET interpretation: the ratio of the geometric mean value of ghrelin (at baseline) for UC vs. ET is 1.73 (95% CI: 1.61–1.86)].